ONCY news

Oncolytics Biotech announced positive translational data from SITC 2026 showing that its oncolytic virus pelareorep, combined with a checkpoint inhibitor, increases HPV-16-specific T cells and tumor-infiltrating lymphocytes in anal cancer patients, potentially broadening its efficacy across HPV-driv…

Oncolytics Biotech's updated Phase 1/2 study shows a 15-month median duration of response for pelareorep combined with an immuno-oncology therapy in anal cancer, surpassing the current standard of care.

The company is displaying data from its study of pelareorep in colorectal cancer at the annual ESMO conference. Positive results from a previous trial support accelerated approval potential for this regulatory pathway.

Oncolytics announced the completion of GOBLET enrollment and expects the final payment from the Pancreatic Cancer Action Network in the fourth quarter. The company expects initial Cohort 5 results in the first half of 2027.

Oncolytics Biotech Inc has secured new patent protection for pelareorep worldwide and obtained a method-of-use patent for its immunotherapy, with U.S. issuance expected soon and new protective applications planned.

Oncolytics Biotech Inc. announced data demonstrating that its investigational candidate pelareorep transforms immunologically inactive liver tumors into a 'hot' phenotype susceptible to immune-based therapies. The positive clinical data strengthens the company's narrative of pelareorep as a backbone…

Nearly all planned clinical sites for the REO 033 study are activated, and multiple patients are currently enrolled. The company expects to provide an interim clinical update by year-end based on objective response rate data.

The company reported that combining its drug pelareorep with a RAS inhibitor maintained anticancer activity, supporting clinical investigation to combat therapy resistance.

Oncolytics Biotech received Fast Track designation for pelareorep in second-line and later anal cancer, which the company believes validates an estimated $1 billion market. This is the company's third Fast Track designation in gastrointestinal cancers.

Oncolytics Biotech announced plans to hold a Type D meeting with the FDA to design a registrational study for its REO 033 colorectal cancer trial. This regulatory step targets accelerated approval and reflects ongoing confidence in the company's clinical data and immunotherapy pipeline.

Oncolytics Biotech announced a newly issued USPTO patent protecting its proprietary manufacturing process for pelareorep, providing intellectual property protection until 2044. The patent strengthens the company's ability to produce pelareorep at commercial scale while supporting its broader strateg…

Oncolytics Biotech appointed Steve Glover, former Ambrx chairman, to its board of directors and promoted John McAdory to Chief Operating Officer to oversee clinical operations and business development. The moves signal organizational strengthening as the company advances pelareorep immunotherapy pro…

Oncolytics Biotech announced initial preclinical findings showing pelareorep demonstrated greater anti-tumor activity in combination with RAS-targeted approaches compared to individual treatments in solid tumor models. The company plans additional studies in pancreatic and colorectal cancer models w…

Oncolytics Biotech announced translational data from GOBLET and AWARE-1 trials will be presented at ASCO 2026, demonstrating pelareorep's immune activation mechanisms in gastrointestinal tumors. The data showing expansion of tumor-specific T cells and correlation with tumor regression supports the c…